Kinfo
Organogenesis Holdings Inc. Class A Common Stock logo

Organogenesis Holdings Inc. Class A Common Stock

ORGONASDAQHealthcare·US · USD
$1.29
-0.04 (-3.01%)
Prices as of October 5, 2026 · market closed

Price

Key statistics

Valuation
Market cap171.14M USD
Enterprise value331.85M USD
Trailing P/E17.07
Forward P/E-4.29
PEG ratio0.03
Price / sales0.37
Price / book1.15
Profitability
Gross margin44.70%
Operating margin-119.25%
Profit margin-18.40%
Return on assets-4.11%
Return on equity-25.92%
Income (TTM)
Revenue457.45M USD
Gross profit327.02M USD
EBITDA93.98M USD
Net income-101.68M USD
Diluted EPS-$0.75
Rev. growth (YoY)-56.70%
Balance sheet
Total cash46.10M USD
Total debt66.95M USD
Debt / equity23.24
Current ratio3.52
Book value / share$1.15
Cash flow (TTM)
Operating cash flow31.97M USD
Levered free cash flow28.45M USD
Shares & price
Shares outstanding128.67M
Float61.06M
Held by institutions51.68%
Beta1.29
50-day MA$1.77
200-day MA$2.76
52-week high$7.08
52-week low$1.32
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-06-0.35-0.69−97.14%2026-07-241.551.68+8.39%2026-05-181.351.50+11.11%2026-05-07-0.29-0.34−17.24%2026-03-20-0.18-0.15+16.67%
About Organogenesis Holdings Inc. Class A Common Stock

Organogenesis Holdings Inc. Class A Common Stock represents ownership in Organogenesis Holdings Inc., a regenerative medicine company focused on developing, manufacturing, and commercializing products for advanced wound care and surgical and sports medicine. The company’s portfolio includes bioactive and acellular biomaterials designed to support healing across chronic and acute wound applications, as well as surgical biologics used in orthopedic and spine-related settings. Its products are used by healthcare providers across hospitals, clinics, and other care environments that treat patients with complex wounds and tissue repair needs. Organogenesis Holdings Inc. serves a specialized role in the broader healthcare market by supplying biologic and tissue-based solutions aimed at improving clinical care pathways in wound management and regenerative therapies. The company is headquartered in Canton, Massachusetts.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Gary S. Gillheeney Sr.
Employees
869
Headquarters
Canton, MA, United States

Frequently asked questions about Organogenesis Holdings Inc. Class A Common Stock